BLOC1S5

Chr 6AR

biogenesis of lysosomal organelles complex 1 subunit 5

Also known as: BLOS5, HPS11, MU, MUTED

This gene encodes a component of BLOC-1 (biogenesis of lysosome-related organelles complex 1). Components of this complex are involved in the biogenesis of organelles such as melanosomes and platelet-dense granules. A mouse model for Hermansky-Pudlak Syndrome is mutated in the murine version of this gene. Alternative splicing results in multiple transcript variants. Read-through transcription exists between this gene and the upstream EEF1E1 (eukaryotic translation elongation factor 1 epsilon 1) gene, as well as with the downstream TXNDC5 (thioredoxin domain containing 5) gene. [provided by RefSeq, Dec 2010]

GeneReviewsOMIMResearchGenerating clinical summary…
MultiplemechanismARLOEUF 1.811 OMIM phenotype
Clinical SummaryBLOC1S5
🧬
Gene-Disease Validity (ClinGen)
Hermansky-Pudlak syndrome 11 · ARDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
7 unique Pathogenic / Likely Pathogenic· 39 VUS of 56 total submissions
📖
GeneReview available — BLOC1S5
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?
1.81LOEUF
pLI 0.000
Z-score -0.57
OE 1.19 (0.761.81)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?
-0.25Z-score
OE missense 1.07 (0.921.25)
109 obs / 101.9 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios?
LoF OE?1.19 (0.761.81)
00.351.4
Missense OE?1.07 (0.921.25)
00.61.4
Synonymous OE?1.06
01.21.6
LoF obs/exp: 12 / 10.1Missense obs/exp: 109 / 101.9Syn Z: -0.27

This gene — mechanism propensity

DN
0.7033th %ile
GOF
0.6931th %ile
LOF
0.4135th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative, gain-of-function and loss-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median
GOFprediction above median
LOF71% of P/LP variants are LoF

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

ClinVar Variant Classifications

56 submitted variants in ClinVar

Classification Summary

Pathogenic3
Likely Pathogenic4
VUS39
Likely Benign8
Benign1
3
Pathogenic
4
Likely Pathogenic
39
VUS
8
Likely Benign
1
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
1
1
1
0
3
Likely Pathogenic
4
0
0
0
4
VUS
0
39
0
0
39
Likely Benign
0
6
0
2
8
Benign
0
0
1
0
1
Total5462255

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

31 pathogenic / likely-pathogenic (of 32) ClinVar copy-number / structural variants overlap BLOC1S5 — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

BLOC1S5 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →